Glucagon-like peptide-1 receptor agonists and pancreatic cancer : a meta-analysis with trial sequential analysis

Detalhes bibliográficos
Autor(a) principal: Pinto, Lana Catani Ferreira
Data de Publicação: 2019
Outros Autores: Falcetta, Mariana Rangel Ribeiro, Rados, Dimitris Rucks Varvaki, Leitão, Cristiane Bauermann, Gross, Jorge Luiz
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFRGS
Texto Completo: http://hdl.handle.net/10183/218669
Resumo: We aimed to assess if GLP-1 agonists are associated with pancreatic cancer. Systematic review and meta-analysis of randomized trials with GLP-1 agonists as an intervention was performed. Trial sequential analysis (TSA) was performed to assess if the available information is sufficient to reject this association. Twelve trials met the study criteria, with a total of 36, 397 patients. GLP-1 analogues did not increase the risk for pancreatic cancer when compared to other treatments (OR 1.06; 95% CI 0.67 to 1.67; I2 14%). TSA confirmed that enough patients were randomized and again no association of the medications and pancreatic cancer was observed considering a NNH of 1000 and the short mean follow-up of the included trials (1.7 years). Larger studies with longer duration would be required to exclude a greater NNH and to aside concerns regarding possible influence of study duration and the outcome.
id UFRGS-2_c585f503fa3df1bfb659c04069280980
oai_identifier_str oai:www.lume.ufrgs.br:10183/218669
network_acronym_str UFRGS-2
network_name_str Repositório Institucional da UFRGS
repository_id_str
spelling Pinto, Lana Catani FerreiraFalcetta, Mariana Rangel RibeiroRados, Dimitris Rucks VarvakiLeitão, Cristiane BauermannGross, Jorge Luiz2021-03-12T04:19:53Z20192045-2322http://hdl.handle.net/10183/218669001122894We aimed to assess if GLP-1 agonists are associated with pancreatic cancer. Systematic review and meta-analysis of randomized trials with GLP-1 agonists as an intervention was performed. Trial sequential analysis (TSA) was performed to assess if the available information is sufficient to reject this association. Twelve trials met the study criteria, with a total of 36, 397 patients. GLP-1 analogues did not increase the risk for pancreatic cancer when compared to other treatments (OR 1.06; 95% CI 0.67 to 1.67; I2 14%). TSA confirmed that enough patients were randomized and again no association of the medications and pancreatic cancer was observed considering a NNH of 1000 and the short mean follow-up of the included trials (1.7 years). Larger studies with longer duration would be required to exclude a greater NNH and to aside concerns regarding possible influence of study duration and the outcome.application/pdfengScientific reports. London. vol. 9 (2019), 2375, 6 f.Receptores de peptídeos semelhantes ao glucagonNeoplasias pancreáticasGlucagon-like peptide-1 receptor agonists and pancreatic cancer : a meta-analysis with trial sequential analysisEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001122894.pdf.txt001122894.pdf.txtExtracted Texttext/plain24410http://www.lume.ufrgs.br/bitstream/10183/218669/2/001122894.pdf.txt4617def856a27b22a889f9c9207e009bMD52ORIGINAL001122894.pdfTexto completo (inglês)application/pdf1018732http://www.lume.ufrgs.br/bitstream/10183/218669/1/001122894.pdfea7e3f8d0702035b8414caecb74cf194MD5110183/2186692021-05-07 04:50:43.493122oai:www.lume.ufrgs.br:10183/218669Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2021-05-07T07:50:43Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.pt_BR.fl_str_mv Glucagon-like peptide-1 receptor agonists and pancreatic cancer : a meta-analysis with trial sequential analysis
title Glucagon-like peptide-1 receptor agonists and pancreatic cancer : a meta-analysis with trial sequential analysis
spellingShingle Glucagon-like peptide-1 receptor agonists and pancreatic cancer : a meta-analysis with trial sequential analysis
Pinto, Lana Catani Ferreira
Receptores de peptídeos semelhantes ao glucagon
Neoplasias pancreáticas
title_short Glucagon-like peptide-1 receptor agonists and pancreatic cancer : a meta-analysis with trial sequential analysis
title_full Glucagon-like peptide-1 receptor agonists and pancreatic cancer : a meta-analysis with trial sequential analysis
title_fullStr Glucagon-like peptide-1 receptor agonists and pancreatic cancer : a meta-analysis with trial sequential analysis
title_full_unstemmed Glucagon-like peptide-1 receptor agonists and pancreatic cancer : a meta-analysis with trial sequential analysis
title_sort Glucagon-like peptide-1 receptor agonists and pancreatic cancer : a meta-analysis with trial sequential analysis
author Pinto, Lana Catani Ferreira
author_facet Pinto, Lana Catani Ferreira
Falcetta, Mariana Rangel Ribeiro
Rados, Dimitris Rucks Varvaki
Leitão, Cristiane Bauermann
Gross, Jorge Luiz
author_role author
author2 Falcetta, Mariana Rangel Ribeiro
Rados, Dimitris Rucks Varvaki
Leitão, Cristiane Bauermann
Gross, Jorge Luiz
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Pinto, Lana Catani Ferreira
Falcetta, Mariana Rangel Ribeiro
Rados, Dimitris Rucks Varvaki
Leitão, Cristiane Bauermann
Gross, Jorge Luiz
dc.subject.por.fl_str_mv Receptores de peptídeos semelhantes ao glucagon
Neoplasias pancreáticas
topic Receptores de peptídeos semelhantes ao glucagon
Neoplasias pancreáticas
description We aimed to assess if GLP-1 agonists are associated with pancreatic cancer. Systematic review and meta-analysis of randomized trials with GLP-1 agonists as an intervention was performed. Trial sequential analysis (TSA) was performed to assess if the available information is sufficient to reject this association. Twelve trials met the study criteria, with a total of 36, 397 patients. GLP-1 analogues did not increase the risk for pancreatic cancer when compared to other treatments (OR 1.06; 95% CI 0.67 to 1.67; I2 14%). TSA confirmed that enough patients were randomized and again no association of the medications and pancreatic cancer was observed considering a NNH of 1000 and the short mean follow-up of the included trials (1.7 years). Larger studies with longer duration would be required to exclude a greater NNH and to aside concerns regarding possible influence of study duration and the outcome.
publishDate 2019
dc.date.issued.fl_str_mv 2019
dc.date.accessioned.fl_str_mv 2021-03-12T04:19:53Z
dc.type.driver.fl_str_mv Estrangeiro
info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10183/218669
dc.identifier.issn.pt_BR.fl_str_mv 2045-2322
dc.identifier.nrb.pt_BR.fl_str_mv 001122894
identifier_str_mv 2045-2322
001122894
url http://hdl.handle.net/10183/218669
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.pt_BR.fl_str_mv Scientific reports. London. vol. 9 (2019), 2375, 6 f.
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRGS
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Repositório Institucional da UFRGS
collection Repositório Institucional da UFRGS
bitstream.url.fl_str_mv http://www.lume.ufrgs.br/bitstream/10183/218669/2/001122894.pdf.txt
http://www.lume.ufrgs.br/bitstream/10183/218669/1/001122894.pdf
bitstream.checksum.fl_str_mv 4617def856a27b22a889f9c9207e009b
ea7e3f8d0702035b8414caecb74cf194
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv
_version_ 1798487457651490816

Registros relacionados